ENTITY
Zai Lab Ltd

Zai Lab Ltd (ZLAB US)

141
Analysis
Health Care • China
Zai Lab Limited operates as a bio-pharmaceutical company. The Company researches and develops therapeutic technology for antibody-based oncology, autoimmune, and infectious diseases treatments. Zai Lab also manufactures drugs in the form of capsules, injections, and liquids. Zai Lab serves patients worldwide.
more
bullish•Chindata Group
•27 Sep 2020 08:46

ECM Weekly (27 September 2020) - Ant Group, Chindata, SCG Packaging, JHBP/Genor, Neuedu, UTI AMC

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Deal...

Share
bullish•Zai Lab Ltd
•25 Sep 2020 09:32

Zai Lab HK Trading - Interest and Behaviour in Line with Huazhu, Highest Concentration so Far

Zai Lab Ltd (ZLAB US)Ā plans to raise around US$1bn in its secondary listing in Hong Kong. We have covered the company's listing and some of its...

Logo
540 Views
Share
bullish•Huazhu Group
•21 Sep 2020 16:46

Huazhu Group Secondary Listing: Trading Debut

Yum China Holdings Inc (9987 HK)Ā will commence trading in Hong Kong on Thursday, 10 September.Ā Yum China Holdings, Inc (YUMC US)Ā priced its Hong...

Logo
379 Views
Share
bullish•Huazhu Group
•21 Sep 2020 10:05

Huazhu HK Secondary Listing Trading - Lowest Coverage, Biggest Correction, Highest Concentration

Huazhu Group (HTHT US) raised around US$900m in its secondary listing in Hong Kong. I have covered the background of the deal in my earlier...

Logo
469 Views
Share
bullish•Zai Lab Ltd
•20 Sep 2020 03:58

Zai Lab Secondary Listing: HK-ADS Premium/​​(Discount) Views

ZTO Express (ZTO US)Ā has launched a $1.6 billion secondary listing in Hong Kong. We previouslyĀ outlined our viewsĀ on ZTO Express’ fundamentals and...

Logo
419 Views
Share
x